Stephen Liu

Associate Professor

Georgetown University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stephen Liu is an Associate Professor at Georgetown University School of Medicine in the United States. His research primarily focuses on the treatment of various types of lung cancer, including extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). Recent publications by Professor Liu cover topics such as maintenance therapy for ES-SCLC, first-in-human studies of innovative treatments, and real-world outcomes of combination therapies for metastatic lung cancers.

Articles (22)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Matthew Krebs

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

View details

Joshua Reuss

Assistant Professor of Medicine

UNITED STATES

View details

Paula Pohlmann

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sarina Piha-Paul

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Charu Aggarwal

University of Pennsylvania

UNITED STATES

View details

Lyudmila Bazhenova

University of California

UNITED STATES

View details

Marialuisa Lavitrano

Full Professor

University of Milano-Bicocca

ITALY

View details

Adam Patterson

Associate Professor

University of Auckland

NEW ZEALAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stephen Liu

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer

A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies

Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States

Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan

Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations

Recent advances and future strategies in first-line treatment of ES-SCLC

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

NRG1 Fusions in NSCLC: Being eNRGy Conscious

Zipalertinib in EGFR Exon 20–Mutant Non–Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting

Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping

NRG1 fusions: Biology to therapy

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Collaborators (8)

Matthew Krebs

Joshua Reuss

Paula Pohlmann

Sarina Piha-Paul

Charu Aggarwal

Lyudmila Bazhenova

Marialuisa Lavitrano

Adam Patterson

Make your next move.